share_log

格隆汇公告精选(港股)︱B站发布2023年Q4及全年财报:毛利率连续六季度提升,全年实现正向经营现金流

Selected GLONGHUI Announcements (Hong Kong Stock) | Site B Releases 2023 Q4 and Annual Financial Report: Gross Margin Increased for Six Consecutive Quarters, Achieving Positive Operating Cash Flow Throughout the Year

Gelonghui Finance ·  Mar 7 09:51

[Today's focus]

Station B released financial reports for Q4 and the full year of 2023: gross margin increased for six consecutive quarters, achieving positive operating cash flow throughout the year

On March 7, Beijing time (March 7, EST), Bilibili (NASDAQ: BILI, HKEX: 9626; hereinafter referred to as “Station B”) announced unaudited financial reports for the fourth quarter and full year ending December 31, 2023. Financial reports show that in 2023, Station B's total revenue for the full year reached RMB 22.53 billion, of which total revenue for the fourth quarter reached RMB 6.35 billion.

In 2023, while ensuring high-quality user growth, Station B will continue to improve operational efficiency and turn high-quality traffic into commercial revenue. In the fourth quarter, Station B had more than 100 million daily active users, 336 million monthly active users, and an average daily usage time of over 95 minutes. As commercialization capabilities and operational efficiency continued to improve, advertising revenue increased 28% year over year in the fourth quarter, gross margin increased to 26.1% for 6 consecutive quarters, and adjusted net loss narrowed sharply by 58% year on year. The net operating cash inflow for the fourth quarter was 640 million yuan, and positive operating cash flow was achieved throughout the year.

Chen Rui, Chairman and CEO of Station B, said, “2023 will be a year of both opportunities and challenges. Over the past year, we have achieved healthy community growth, improved our commercialization capabilities and operational efficiency, and drastically reduced our losses. In the fourth quarter, the average daily active users of Station B exceeded 100 million, and the average daily usage time of users exceeded 95 minutes. We continue to promote commercialization capacity building so that more creators can earn revenue at Station B. In 2023, over 3 million creators received revenue at Station B, an increase of 30% over the previous year. In the fourth quarter, revenue from advertising and value-added services increased by 28% and 22%, respectively, truly achieving a positive cycle between community and business. As operating efficiency improved, Station B's gross profit increased 33% year-on-year in the fourth quarter, while gross margin continued to rise 26.1% for 6 consecutive quarters. Adjusted net loss for the full year narrowed 49% year over year, and positive operating cash flow for the whole year was achieved. Looking ahead to 2024, we will continue to drive a positive cycle of community and business to create value for users, creators, and partners.”

[Important matters]

BOC International (03329.HK): Establishing a digital yuan marketing service framework agreement

[Financial results]

MTR Corporation (00066.HK)'s total revenue in 2023 reached HK$56.982 billion, up 19.2% year-on-year

Prada (01913.HK)'s annual EBIT increased by 36.8% to €1,062 million, with a dividend of €0.137 per share

Fuzhikang Group (02038.HK) annual net loss attributable to owners increased to US$121 million

Yeju Healthcare (06929.HK): Profit increased 73.1% year-on-year to US$46.2 million during the adjusted year in 2023

MONGOL MINING (00975.HK) expects annual profit of US$220 million to US$240 million

Tomson Group (00258.HK) expects net profit to increase sharply by about 145%-150% in 2023

Happy Meet Group (02473.HK) Yingxi: Profit attributable to owners is expected to increase by more than 30.5% in FY2023

Jiayao Holdings (01626.HK) Yingxi: Expected annual profit after tax of about 110 million to 150 million yuan

Huafu Construction Finance (00952.HK) Profit: Expected annual comprehensive profit before tax is approximately HK$116 million to HK$136 million

White Flower Oil (00239.HK) Yingxi: The consolidated net profit is expected to increase significantly to about HK$100 million in 2023

Lifou China (02136.HK) Yingxi: Expected profit attributable to company owners is about 82 million yuan to 90 million yuan in 2023

Dongying Tour (06882.HK) Yingxi: Expected net profit for fiscal year 2023 is approximately HK$71.7 million

A8 New Media (00800.HK) Yingxi: Expected annual net profit of 20 million to 30 million yuan

Tianjin Port Development (03382.HK): Annual net profit is expected to increase 110% to 120% year-on-year

Shenwei Pharmaceutical (02877.HK) Yingxi: Net profit is expected to increase 30% to 36% year-on-year in 2023

Yimei International Holdings (01870.HK) Profit: Expected to turn a loss into a profit of over HK$17 million in the year

Yingda Highway Renewable Technology (06888.HK) Yingxi: Expected net profit for 2023 is about HK$12 million

Qilu Express (01576.HK): 2023 profit and total comprehensive income are expected to decrease by about 31.56% year-on-year

Jinke Services (09666.HK) Profit Alert: Expected net loss of about 800 million yuan to 1.1 billion yuan in 2023

[Operational data]

Xuhui Holding Group (00884.HK): cumulative contract sales of 5.96 billion yuan in January-February

Xintian Green Energy (00956.HK) completed 1.05 million megawatt-hours of power generation in February, a year-on-year decrease of 8.33%

Jieli Trading Bank (08017.HK): The number of registered users reached 809,600 in February, up 6.1% year-on-year

[Pharmaceutical Innovation]

Shanghai Pharmaceutical (02607.HK): Citicin Choline Sodium Injection Passed Generic Drug Consistency Evaluation

Fosun Pharmaceutical (02196.HK): Clinical trials of XS-02 capsules for the treatment of advanced solid tumors were approved

Yuanda Pharmaceutical (00512.HK): A new drug marketing application for the global innovative hormone nano-suspension eye drops was approved by the US FDA

Yuanda Pharmaceutical (00512.HK): Global innovative ophthalmic drug GPN00884 approved to conduct phase I clinical research in China

[Equity Incentives]

IMAX CHINA (01970.HK) grants 1.041,700 restricted share units and 254,300 performance share units

Zaiding Pharmaceutical (09688.HK): Grant of 39,800 share options and 371,000 restricted share units

[Issuance of additional shares]

The stock offering to China International (01871.HK) was subscribed to approximately 16.01%

China Hong Kong Energy (00931.HK) plans to allocate a total of 697.7 million capitalized shares

[Repurchase Cancellation]

HSBC Holdings (00005.HK) spent HK$180 million to repurchase 29.684 million shares on March 6

Standard Chartered Group (02888.HK) spent £21.13,000 to buy back 3.088,600 shares on March 6

Shell-W (02423.HK) spent 15.46 million US dollars to buy back 3.66 million shares on March 6

AIA (01299.HK) spent HK$71.628,800 to buy back 1.194,200 shares on March 7

Kuaishou-W (01024.HK) spent HK$39.987 million to repurchase 871,000 shares on March 7

Yum China (09987.HK) spent HK$27.423 million to buy back 83.75 million shares on March 6

Swire Group A (00019.HK) spent HK$27.17 million to buy back 433,500 shares on March 7

Haitong Securities (06837.HK) spent 14.9876 million yuan to buy back 1.65 million A shares on March 7

Haier Smart Home (06690.HK) spent 7.48 million yuan to buy back 300,000 A shares on March 7

Gloria Ying (06821.HK) buys back 517,200 A-shares for the first time

Junshi Biotech (01877.HK) spent 3 million yuan to buy back 102,500 A shares on March 7

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment